This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision. The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool. The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.
Study Type
OBSERVATIONAL
Enrollment
271
Dana Farber Cancer Institute
Boston, Massachusetts, United States
We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool
Time frame: Up to 5 years
Evaluate Patient Experience With Genetic Testing
Time frame: up to 5 years
Summarize patient satisfaction with Genetic counseling
Time frame: up to 5 years
Number of patients who disclose genetic testing results to relatives
Time frame: up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.